Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) EPS (Weighted Average and Diluted) (2017 - 2018)

Historic EPS (Weighted Average and Diluted) for Gsk (GLAXF) over the last 8 years, with Q1 2018 value amounting to $0.05.

  • Gsk's EPS (Weighted Average and Diluted) rose 71.57% to $0.05 in Q1 2018 from the same period last year, while for Mar 2018 it was $0.05, marking a year-over-year increase of 71.57%. This contributed to the annual value of $0.8 for FY2024, which is 4668.65% down from last year.
  • Gsk's EPS (Weighted Average and Diluted) amounted to $0.05 in Q1 2018, which was up 71.57% from $0.05 recorded in Q1 2017.
  • In the past 5 years, Gsk's EPS (Weighted Average and Diluted) registered a high of $0.05 during Q1 2018, and its lowest value of -$0.0 during Q4 2015.
  • Over the past 4 years, Gsk's median EPS (Weighted Average and Diluted) value was $0.02 (recorded in 2014), while the average stood at $0.02.
  • Per our database at Business Quant, Gsk's EPS (Weighted Average and Diluted) surged by 468.85% in 2014 and then crashed by 10881.19% in 2015.
  • Quarter analysis of 4 years shows Gsk's EPS (Weighted Average and Diluted) stood at $0.0 in 2014, then plummeted by 108.81% to -$0.0 in 2015, then skyrocketed by 2390299.2% to $0.05 in 2017, then rose by 0.72% to $0.05 in 2018.
  • Its EPS (Weighted Average and Diluted) was $0.05 in Q1 2018, compared to $0.05 in Q1 2017 and -$0.0 in Q4 2015.